Rytelo Patent Expiration

Rytelo is a drug owned by Geron Corp. It is protected by 4 US drug patents filed in 2024. Out of these, 2 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 15, 2033. Details of Rytelo's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US7494982 Modified oligonucleotides for telomerase inhibition
Dec, 2025

(1 year, 13 days from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375485 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
Mar, 2033

(8 years from now)

Active
US9388415 Modified oligonucleotides for telomerase inhibition
Sep, 2024

(3 months ago)

Expired
US9388416 Modified oligonucleotides for telomerase inhibition
Sep, 2024

(3 months ago)

Expired


FDA has granted several exclusivities to Rytelo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Rytelo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Rytelo.

Exclusivity Information

Rytelo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Rytelo's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-482) Jun 06, 2031

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Rytelo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rytelo's family patents as well as insights into ongoing legal events on those patents.

Rytelo's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Rytelo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 15, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Rytelo Generics:

There are no approved generic versions for Rytelo as of now.





About Rytelo

Rytelo is a drug owned by Geron Corp. Rytelo uses Imetelstat Sodium as an active ingredient. Rytelo was launched by Geron in 2024.

Approval Date:

Rytelo was approved by FDA for market use on 06 June, 2024.

Active Ingredient:

Rytelo uses Imetelstat Sodium as the active ingredient. Check out other Drugs and Companies using Imetelstat Sodium ingredient

Dosage:

Rytelo is available in powder form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 47MG BASE/VIAL POWDER Prescription INTRAVENOUS
EQ 188MG BASE/VIAL POWDER Prescription INTRAVENOUS